Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EG-70 intravesical master protocol in non-muscle invasive bladder cancer
2024-512900-20-00Phase 2Authorised
- Sponsor
- enGene
- Start
- Jan 2025
- Modality
- Small Molecules, Lipid-mediated Delivery → Gene Addition/Replacement → Gene Therapies, Electrical: Electroporation → Physical Methods → Gene Addition/Replacement → Gene Therapies
- Countries
- 10
01
Overview
Phase 2, open-label trial of detalimogene voraplasmid and polidocanol in non-muscle-invasive bladder cancer (NMIBC) and transitional cell carcinoma (TCC) (6 arms), sponsored by enGene. Primary endpoints: Cystoscopic complete response at any time, Bladder rinse substudy safety and 2 more. Planned start Jan 2025; status: authorised.
02
Drugs
detalimogene voraplasmidpolidocanol
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2024-512900-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512900-20-00.